肌炎、系统性硬化症与特发性肺纤维化的肺移植结局:多中心回顾性分析
该多中心回顾性分析比较了2012-24年间加拿大两中心因间质性肺病接受肺移植的特发性炎性肌病(IIM,n=22)、系统性硬化症(SSc,n=32)和特发性肺纤维化(IPF,n=64)患者的临床特征与移植后结局。结果显示,尽管IIM和SSc患者移植前病情更复杂(如IIM更需ICU和紧急移植),但1年生存率、末次随访生存率及慢性肺移植物功能障碍发生率与IPF无显著差异,且无自身免疫病复发。
要点
- IIM和SSc患者肺移植后生存率与IPF无显著差异。
- IIM患者移植前更需ICU和紧急移植,移植后住院时间更长。
- 未观察到自身免疫病复发。
核心结论
- 尽管存在基础自身免疫病,选择的IIM和SSc患者移植后生存结局与IPF无显著差异。
- 需要紧急移植和ECMO支持的快速进展型ILD的IIM患者生存率与无这些并发症者相似。
- IIM和SSc患者移植前后病程更复杂,强调个体化肺移植策略和多学科管理。
研究设计与样本
- 多中心回顾性分析,纳入2012-24年加拿大温哥华和蒙特利尔两个中心因间质性肺病接受肺移植的患者。
- 样本包括IIM(n=22)、SSc(n=32)和IPF(n=64)患者。
主要发现
- IIM患者中41%就诊时临床无肌病,45%有抗MDA5皮肌炎且均为快速进展型ILD,32%有抗合成酶综合征,14%有重叠肌炎,9%有其他皮肌炎。
- SSc患者中88%有肺动脉高压(31%为重度),78%有食管运动障碍。
- IIM患者移植前更频繁需要ICU入住和紧急移植,移植后ICU/住院时间更长。
- 1年生存率、末次随访生存率(中位随访:IIM 2.8年,SSc 2.5年,IPF 3.6年)、慢性肺移植物功能障碍或恶性肿瘤发生率无显著差异。
- IIM亚组(按移植紧迫性、ECMO支持和无肌病分层)和SSc亚组(按重度肺动脉高压、食管运动障碍和移植紧迫性分层)的长期生存无显著差异,未观察到自身免疫病复发。
临床怎么用
- 对于选择的IIM和SSc相关ILD患者,肺移植可作为治疗选择,生存结局与IPF相当。
- IIM患者移植前常需紧急评估和ICU支持,移植后住院时间更长,应制定个体化移植策略和多学科管理方案。
局限性
- 回顾性研究设计。
- 样本量较小(IIM n=22,SSc n=32,IPF n=64)。
- 仅纳入两个加拿大中心,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe clinical characteristics and post-lung transplant outcomes of patients with idiopathic inflammatory myopathies (IIM), SSc and idiopathic pulmonary fibrosis (IPF). METHODS: We retrospectively analysed interstitial lung disease (ILD) patients with IIM (n = 22), SSc (n = 32) and IPF (n = 64) who underwent lung transplantation (2012-24) at two Canadian centres, Vancouver and Montréal. RESULTS: Among IIM patients, 41% were clinically amyopathic at presentation, and 45% had anti-melanoma differentiation-associated protein 5 (anti-MDA5) DM, all with rapid progressive (RP)-ILD, 32% anti-synthetase syndrome, 14% overlap myositis and 9% other DM. In SSc, 88% had pulmonary hypertension (PH) (31% severe) and 78% had oesophageal dysmotility. IIM patients required more frequent pre-transplant intensive care unit (ICU) admission and emergency transplantation. Post-transplant, IIM patients had longer ICU/hospital stays. There were no significant differences in 1-year survival, survival at last follow-up (median: 2.8 years for IIM, 2.5 years for SSc and 3.6 years for IPF), incidence of chronic lung allograft dysfunction or malignancy. Subgroup analyses of IIM [stratified by transplant urgency, extracorporeal membrane oxygenation (ECMO) support and amyopathy] and SSc (stratified by severe PH, oesophageal dysmotility and transplant urgency) showed no significant differences in long-term survival. No autoimmune disease recurrence was observed. CONCLUSION: Despite their underlying autoimmune diseases, post-transplant survival outcomes of selected IIM and SSc patients did not differ significantly from those with IPF. IIM patients with RP-ILD necessitating emergency transplantation and ECMO support exhibited survival similar to those without such complications. However, their more complex pre- and post-transplant courses emphasize the necessity for individualized lung transplant strategies and a multidisciplinary management approach.
引用
- Chang A, Saleh N, Yu A, et al. Lung transplant outcomes in myositis, systemic sclerosis and idiopathic pulmonary fibrosis: a multicentre retrospective analysis. Rheumatology (Oxford). 2026. PMID: 41984803. doi:10.1093/rheumatology/keag200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。